VistaGen Therapeutics
VTGN
55 hedge funds and large institutions have $8.84M invested in VistaGen Therapeutics in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 16 closing their positions.
20% more call options, than puts
Call options by funds: $776K | Put options by funds: $644K
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
5% less funds holding
Funds holding: 58 → 55 (-3)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
41.33% less ownership
Funds ownership: 76.15% → 34.82% (-41%)
89% less capital invested
Capital invested by funds: $81.8M → $8.84M (-$73M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$1.84M |
| 2 |
LM
Luminus Management
Houston,
Texas
|
+$1.26M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$900K |
| 4 |
Jane Street
New York
|
+$811K |
| 5 |
Millennium Management
New York
|
+$637K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$14.7M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$7.02M |
| 3 |
SC
Stempoint Capital
New York
|
-$6.76M |
| 4 |
CC
Commodore Capital
New York
|
-$5.59M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.95M |
VTGN Hedge Fund Activity: Q4 2025 in Review
55 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2025, worth a combined $8.84M — down 89% from $81.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of VTGN and 14 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 18 added.
The largest buyer was ADAR1 Capital Management, adding an estimated $1.84M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $14.7M sold.
- 55 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2025, down from 58 in Q3 2025.
- Funds reported $8.84M of VistaGen Therapeutics stock for Q4 2025, down 89% quarter-over-quarter.
- 14 funds opened new VistaGen Therapeutics positions in Q4 2025 and 16 closed out, a net change of -2 holders.
- The largest VistaGen Therapeutics buyer in Q4 2025 was ADAR1 Capital Management, an estimated $1.84M added.
- The largest VistaGen Therapeutics seller in Q4 2025 was Janus Henderson Group, an estimated $14.7M sold.
Based on aggregated 13F filings for Q4 2025.